In many immunohistochemical studies, nuclear survivin expression is an unfavorable factor for prognosis, including prostate cancer [31], rectal cancer [32], esophageal squamous cell carcinoma [11], colorectal carcinoma [8], soft-tissue sarcoma [19], breast cancer [9], laryngeal squamous cell carcinoma [12], hepatocellular carcinoma [33], ovarian carcinoma [34], non-small cell lung carcinoma [10], and glioblastoma [13]. Here, BIRC5 is linked to breast cancer.